Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Validation of the immune-mediated colitis endoscopic score using a retrospective cohort of patients with immune-mediated colitis.

iGIE : innovation, investigation and insights·2026

Same author

Human CD8-iTreg are potent GVHD suppressors and tumoricidal effectors by release of Granzyme-K <sup>+</sup> Supramolecular Attack Particles.

bioRxiv : the preprint server for biology·2026

Same author

Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Effect of icosapent ethyl treatment on colorectal tissue marine omega-3 polyunsaturated fatty acid levels among patients with a history of adenoma: a prospective, single-arm clinical trial.

The American journal of clinical nutrition·2026

Same author

Activation-dependent lentiviruses enable antigen-specific T cell expansion and transduction.

bioRxiv : the preprint server for biology·2026

Same author

Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancer.

Cancer cell·2026

Same journal

The Neuroimmune Circuitry of Peripheral Sensory Neuron Subtypes in Chronic Pain.

Annual review of immunology·2026

Same journal

The Spectrum of Fibroblast Immune Biology.

Annual review of immunology·2026

Same journal

The Molecular Logic of Immunoglobulin Heavy Chain Class Switch Recombination.

Annual review of immunology·2026

Same journal

Decoding Human T Cell Immunity with Artificial Intelligence and Single-Cell Genomics.

Annual review of immunology·2026

Same journal

Immune Niches in Cancer.

Annual review of immunology·2026

Same journal

T Cell Receptor Signaling and Immune Tolerance: From Autoimmunity to Cancer Immunity.

Annual review of immunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Immune therapy for cancer.

Michael Dougan¹, Glenn Dranoff

¹Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.

Annual Review of Immunology

|November 15, 2008

Summary

This summary is machine-generated.

Cancer immunotherapy, including monoclonal antibodies and vaccines, is a cornerstone of modern treatment. Future strategies aim to enhance antitumor immune responses for more effective cancer therapies.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Experiment Videos

Last Updated: Jun 28, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Area of Science:

Oncology
Immunology
Cancer Therapeutics

Background:

Immunotherapy has emerged as a standard cancer treatment over the last decade.
Key therapies include monoclonal antibodies, immune adjuvants, and vaccines for oncogenic viruses.
Immune modulation and activation are crucial in supportive care for chemotherapy and bone marrow transplantation.

Purpose of the Study:

To review advances in understanding tumor-immune interactions.
To highlight novel investigational immunotherapies.
To discuss future directions for enhancing immune-based cancer treatments.

Main Methods:

Review of current and emerging immunotherapeutic strategies.
Analysis of molecular interactions between tumors and the immune system.
Exploration of approaches to augment antitumor immune responses.

Main Results:

Established immunotherapies (monoclonal antibodies, adjuvants, vaccines) are effective.
Immune activation is central to bone marrow transplant efficacy.
Novel approaches focus on expanding T cells, immune stimulation, and antagonizing tolerance pathways.

Conclusions:

Advances in understanding tumor-immune interactions drive novel therapeutic development.
Future cancer immunotherapy will likely combine multiple approaches.
Combined strategies aim to generate more potent and effective cancer treatments.